Nominate your peers and colleagues for HFSA Awards through February 27!

Heart Failure Beat: Heart Failure Science: Top Takeaways from 2022 Part II

The program's hosts, Michael Beasley, MD and Priya Umapathi, MD, interview the current and immediate-past presidents of the HFSA, Drs. John Teerlink and Mark Drazner, discussing the most significant developments in heart failure cardiology during 2022.

Heart Failure Science: Top Takeaways from 2022 Part II

On part two of this episode series, hosts Michael Beasley, MD and Priya Umapathi, MD continue their discussion on the top highlights of 2022 with current HFSA president Dr. John Teerlink. The STRONG-HF clinical trial, the future of Omecamtiv Mecarbil and the METEORIC-HF trial are discussed. Priya introduces her new episode segment "From Failure to Function," which summarizes the latest heart failure research presented at meetings around the world.

Listen below and subscribe: Apple PodcastsGoogle Podcasts, SpotifyPodcast Home

Featuring

Hosts: 

  • Michael Beasley, MD, Assistant Professor of Medicine at the Yale New Haven Hospital @MHBeasleyMD

  • Priya Umapathi, MD Assistant Professor in the Division of Cardiology & Advanced Heart Failure and Heart Transplant Cardiologist at Johns Hopkins Hospital @priyaumapathi

Guest: 

  • John Teerlink, MD, FHFSA, HFSA President and Director of Heart Failure and Echocardiography Laboratory at San Francisco Veterans Affairs Medical Center, San Francisco, CA @johnteerlinkmd
     


References / Notes

Important Note: At the time of this recording, the U.S. Food & Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) vote on omecamtiv mecarbil had not occurred. As of December 13, 2022, the committee “voted 8 to 3 that the benefits of omecamtiv mecarbil do not outweigh its risks for the treatment of heart failure with reduced ejection fraction (HFrEF).” Read the full press release.